CU22545A1
(es)
*
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
WO1998011241A1
(en)
*
|
1996-09-16 |
1998-03-19 |
Merck Patent Gmbh |
Oligocistronic expression system for the production of heteromeric proteins
|
BR122014028365B8
(pt)
|
1999-06-25 |
2021-07-06 |
Genentech Inc |
artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
MXPA05000403A
(es)
|
2002-07-15 |
2005-07-22 |
Genentech Inc |
Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
|
BR122018071968B8
(pt)
|
2003-11-06 |
2021-07-27 |
Seattle Genetics Inc |
conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
|
EP1699822B1
(en)
*
|
2003-12-30 |
2008-04-23 |
MERCK PATENT GmbH |
Il-7 fusion proteins with antibody portions, their preparation and their use
|
WO2005070020A2
(en)
|
2004-01-23 |
2005-08-04 |
The Regents Of The University Of Colorado |
Gefitinib sensitivity-related gene expression and products and methods related thereto
|
AU2005232657B2
(en)
|
2004-04-08 |
2010-12-16 |
David B. Agus |
ErbB antagonists for pain therapy
|
EP2527460B1
(en)
|
2004-05-27 |
2014-12-24 |
The Regents of The University of Colorado |
Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7449184B2
(en)
|
2005-01-21 |
2008-11-11 |
Genentech, Inc. |
Fixed dosing of HER antibodies
|
PT1850874E
(pt)
|
2005-02-23 |
2013-12-02 |
Genentech Inc |
Extensão de tempo até a progressão da doença ou sobrevivência em pacientes com cancro de ovário usando pertuzumab
|
AR053272A1
(es)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
ATE555125T1
(de)
|
2005-12-30 |
2012-05-15 |
Merck Patent Gmbh |
Interleukin-12p40-varianten mit verbesserter stabilität
|
EA016429B1
(ru)
|
2005-12-30 |
2012-04-30 |
Мерк Патент Гмбх |
Антитела против cd19 с пониженной иммуногенностью
|
MX2008015939A
(es)
*
|
2006-06-16 |
2009-02-11 |
Univ Kumamoto |
Peptidos antigeneticos de rechazo de tumor derivados de sparc y medicamentos que comprenden los mismos.
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
PE20090681A1
(es)
|
2007-03-02 |
2009-06-10 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her
|
CA2690334C
(en)
|
2007-06-08 |
2017-02-14 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
ES2572728T3
(es)
|
2009-03-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HER biespecíficos
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
JP5764127B2
(ja)
*
|
2009-08-17 |
2015-08-12 |
ロシュ グリクアート アーゲー |
標的化イムノコンジュゲート
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
MX2012008049A
(es)
|
2010-01-12 |
2012-08-01 |
Hoffmann La Roche |
Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
US8617557B2
(en)
|
2010-03-12 |
2013-12-31 |
The Regents Of The University Of California |
Antibody fusion with IL-12 proteins with disrupted heparin-binding activity
|
CA2793024A1
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
MX2012011887A
(es)
|
2010-04-16 |
2012-11-30 |
Genentech Inc |
Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt.
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
CN103209695A
(zh)
|
2010-09-15 |
2013-07-17 |
弗·哈夫曼-拉罗切有限公司 |
氮杂苯并噻唑化合物、组合物及应用方法
|
UY33679A
(es)
|
2010-10-22 |
2012-03-30 |
Esbatech |
Anticuerpos estables y solubles
|
EA201390472A1
(ru)
|
2010-10-29 |
2014-02-28 |
Иммьюноджен, Инк. |
Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
|
AU2011320318B9
(en)
|
2010-10-29 |
2015-11-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
EP2640722B1
(en)
|
2010-11-19 |
2015-11-04 |
F.Hoffmann-La Roche Ag |
Pyrazolopyridines and their use as tyk2 inhibitors
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013024011A1
(en)
|
2011-08-12 |
2013-02-21 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
CA2856411A1
(en)
|
2011-11-21 |
2013-05-30 |
Immunogen, Inc. |
Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
|
RU2019103083A
(ru)
|
2011-11-30 |
2019-03-22 |
Дженентек, Инк. |
МУТАЦИИ ErbB3 ПРИ РАКЕ
|
EP2831115A1
(en)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to her3 inhibitors
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
WO2014139326A1
(en)
|
2013-03-13 |
2014-09-18 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
CN105307683A
(zh)
|
2013-03-14 |
2016-02-03 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
AU2014228172B2
(en)
*
|
2013-03-15 |
2018-12-06 |
Abbvie Deutschland Gmbh & Co.Kg |
Anti-EGFR antibody drug conjugate formulations
|
WO2014144850A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
CN104250302B
(zh)
*
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
WO2015035062A1
(en)
|
2013-09-05 |
2015-03-12 |
Genentech, Inc. |
Antiproliferative compounds
|
WO2015049325A1
(en)
|
2013-10-03 |
2015-04-09 |
F. Hoffmann-La Roche Ag |
Therapeutic inhibitors of cdk8 and uses thereof
|
RU2016114074A
(ru)
|
2013-10-18 |
2017-11-23 |
Дженентек, Инк. |
Анти-rspo антитела и способы применения
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
CN106132439A
(zh)
|
2014-03-31 |
2016-11-16 |
豪夫迈·罗氏有限公司 |
包含抗血管发生剂和ox40结合激动剂的组合疗法
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
WO2015150526A2
(en)
*
|
2014-04-03 |
2015-10-08 |
Cellectis |
Cd33 specific chimeric antigen receptors for cancer immunotherapy
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
JP2017529358A
(ja)
|
2014-09-19 |
2017-10-05 |
ジェネンテック, インコーポレイテッド |
がんの処置のためのcbp/ep300阻害剤およびbet阻害剤の使用
|
WO2016057924A1
(en)
|
2014-10-10 |
2016-04-14 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
JP6702991B2
(ja)
|
2014-11-03 |
2020-06-03 |
ジェネンテック, インコーポレイテッド |
T細胞免疫サブセットを検出するためのアッセイ及びその使用の方法
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
JP6639497B2
(ja)
|
2014-11-10 |
2020-02-05 |
ジェネンテック, インコーポレイテッド |
ブロモドメインインヒビターおよびその使用
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
WO2016086200A1
(en)
|
2014-11-27 |
2016-06-02 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
CN107109491A
(zh)
|
2014-12-23 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
用于治疗和诊断化学疗法抗性癌症的组合物和方法
|
WO2016109546A2
(en)
|
2014-12-30 |
2016-07-07 |
Genentech, Inc. |
Methods and compositions for prognosis and treatment of cancers
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
EP3242872B1
(en)
|
2015-01-09 |
2019-07-03 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
JP6889661B2
(ja)
|
2015-01-09 |
2021-06-18 |
ジェネンテック, インコーポレイテッド |
4,5−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ(kdm2b)インヒビターとしてのその使用
|
AU2016206965B2
(en)
|
2015-01-12 |
2021-03-04 |
Children's Medical Center Corporation |
Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
|
WO2016123391A1
(en)
|
2015-01-29 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
RU2746021C2
(ru)
*
|
2015-02-18 |
2021-04-06 |
Ф.Хоффманн-Ля Рош Аг |
Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
WO2016183326A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN107532217A
(zh)
|
2015-05-29 |
2018-01-02 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
KR20180018538A
(ko)
|
2015-06-17 |
2018-02-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
DK3341376T3
(da)
|
2015-08-26 |
2021-03-29 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Kondenserede tricykliske forbindelser som proteinkinase-inhibitorer
|
KR20200087283A
(ko)
|
2015-09-25 |
2020-07-20 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
ES2907574T3
(es)
|
2015-12-16 |
2022-04-25 |
Genentech Inc |
Proceso para la preparación de compuestos inhibidores de pi3k triciclicos y métodos para su utilización para el tratamiento del cáncer.
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
PL3443350T3
(pl)
|
2016-04-15 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Sposoby monitorowania i leczenia nowotworu
|
EP3443114A1
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
MA45146A
(fr)
|
2016-05-24 |
2021-03-24 |
Constellation Pharmaceuticals Inc |
Dérivés de pyrazolopyridine pour le traitement du cancer
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック, インコーポレイテッド |
Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
US20200129519A1
(en)
|
2016-06-08 |
2020-04-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
TWI775781B
(zh)
|
2016-10-06 |
2022-09-01 |
美商建南德克公司 |
癌症之治療性及診斷性方法
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
US20210260162A1
(en)
*
|
2017-03-31 |
2021-08-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthekine compositions and methods of use
|
EP3609537A1
(en)
|
2017-04-13 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
|
AU2018316343A1
(en)
|
2017-08-11 |
2020-02-13 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
EP3679159A1
(en)
|
2017-09-08 |
2020-07-15 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
JP2021502066A
(ja)
|
2017-11-06 |
2021-01-28 |
ジェネンテック, インコーポレイテッド |
がんの診断及び療法
|
US20200399376A1
(en)
|
2018-02-26 |
2020-12-24 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2019226514A2
(en)
|
2018-05-21 |
2019-11-28 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
EP3810653A1
(en)
|
2018-06-23 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
AU2019305637A1
(en)
|
2018-07-18 |
2021-03-11 |
Genentech, Inc. |
Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
JP2022501332A
(ja)
|
2018-09-19 |
2022-01-06 |
ジェネンテック, インコーポレイテッド |
膀胱がんの治療方法および診断方法
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
JP2022512744A
(ja)
|
2018-10-18 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
肉腫様腎臓がんのための診断および治療方法
|
CN112166122A
(zh)
*
|
2018-12-13 |
2021-01-01 |
丁邦 |
抗体-肿瘤坏死因子α融合蛋白及其制法和应用
|
JP2022519649A
(ja)
|
2019-02-08 |
2022-03-24 |
ジェネンテック, インコーポレイテッド |
がんの診断および治療方法
|
WO2020172712A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
BR112021016923A2
(pt)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
CA3133821A1
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
KR20220057563A
(ko)
|
2019-09-04 |
2022-05-09 |
제넨테크, 인크. |
Cd8 결합제 및 이의 용도
|
CA3151406A1
(en)
|
2019-09-27 |
2021-04-01 |
Raymond D. Meng |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CN114728936A
(zh)
|
2019-10-29 |
2022-07-08 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的双功能化合物
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
TW202130618A
(zh)
|
2019-11-13 |
2021-08-16 |
美商建南德克公司 |
治療性化合物及使用方法
|
CA3163950A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
AU2020408562A1
(en)
|
2019-12-20 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
CN115843335A
(zh)
|
2020-06-30 |
2023-03-24 |
国家医疗保健研究所 |
用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法
|
JP2023531305A
(ja)
|
2020-06-30 |
2023-07-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
術前補助療法後の固形癌患者の再発及び/又は死亡のリスクを予測するための方法。
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2022171745A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
AU2022280025A1
(en)
|
2021-05-25 |
2023-12-07 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性kras抑制劑
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|